Cargando…
Compatibility of intravitreally applied epidermal growth factor and amphiregulin
INTRODUCTION: To examine the compatibility of intravitreally injected epidermal growth factor (EGF) and amphiregulin as EGF family member. METHODS: Four rabbits (age: 4 months; body weight: 2.5 kg) received three intravitreal injections of EGF (100 ng) uniocularly in monthly intervals and underwent...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Netherlands
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172503/ https://www.ncbi.nlm.nih.gov/pubmed/33713254 http://dx.doi.org/10.1007/s10792-021-01761-w |
_version_ | 1783702542891352064 |
---|---|
author | Bikbov, Mukharram M. Khalimov, Timur A. Cerrada-Gimenez, Marc Ragauskas, Symantas Kalesnykas, Giedrius Jonas, Jost B. |
author_facet | Bikbov, Mukharram M. Khalimov, Timur A. Cerrada-Gimenez, Marc Ragauskas, Symantas Kalesnykas, Giedrius Jonas, Jost B. |
author_sort | Bikbov, Mukharram M. |
collection | PubMed |
description | INTRODUCTION: To examine the compatibility of intravitreally injected epidermal growth factor (EGF) and amphiregulin as EGF family member. METHODS: Four rabbits (age: 4 months; body weight: 2.5 kg) received three intravitreal injections of EGF (100 ng) uniocularly in monthly intervals and underwent ocular photography, tonometry, biometry, and optical coherence tomography. After sacrificing the rabbits, the globes were histomorphometrically examined. In a second study part, eyes of 22 guinea pigs (age: 2–3 weeks) received two intravitreal administrations of amphiregulin (10 ng) or phosphate buffered solution (PBS) in 10-day interval, or were left untouched. Ten days after the second injection, the guinea pigs were sacrificed, the enucleated eyes underwent histological and immune-histological examinations. RESULTS: The rabbit eyes with EGF injections versus the contralateral untouched eyes did not show significant differences in intraocular pressure (7.5 ± 2.4 mmHg vs. 6.8 ± 2.2 mmHg; P = 0.66), retinal thickness (158 ± 5 µm vs. 158 ± 3 µm; P = 1.0), cell counts in the retinal ganglion cell layer (3.3 ± 1.7 cells/150 µm vs. 3.0 ± 1.4 cells/150 µm; P = 0.83), inner nuclear layer (46.4 ± 23.2 cells/150 µm vs. 39.6 ± 6.4 cells/150 µm; P = 0.61), and outer nuclear layer (215 ± 108 cells/150 µm vs. 202 ± 47 cells/150 µm; P = 0.83), or any apoptotic retinal cells. The guinea pig eyes injected with amphiregulin versus eyes with PBS injections did not differ (P = 0.72) in the degree of microglial activation, and both groups did not differ from untouched eyes in number of apoptotic retinal cells and retinal gliosis. CONCLUSIONS: Intravitreal applications of EGF (100 ng) in rabbits nor intravitreal applications of amphiregulin (10 ng) in guinea pigs led to intraocular specific inflammation or any observed intraocular destructive effect. The findings support the notion of a compatibility of intraocular applied EGF and amphiregulin. |
format | Online Article Text |
id | pubmed-8172503 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Netherlands |
record_format | MEDLINE/PubMed |
spelling | pubmed-81725032021-06-07 Compatibility of intravitreally applied epidermal growth factor and amphiregulin Bikbov, Mukharram M. Khalimov, Timur A. Cerrada-Gimenez, Marc Ragauskas, Symantas Kalesnykas, Giedrius Jonas, Jost B. Int Ophthalmol Original Paper INTRODUCTION: To examine the compatibility of intravitreally injected epidermal growth factor (EGF) and amphiregulin as EGF family member. METHODS: Four rabbits (age: 4 months; body weight: 2.5 kg) received three intravitreal injections of EGF (100 ng) uniocularly in monthly intervals and underwent ocular photography, tonometry, biometry, and optical coherence tomography. After sacrificing the rabbits, the globes were histomorphometrically examined. In a second study part, eyes of 22 guinea pigs (age: 2–3 weeks) received two intravitreal administrations of amphiregulin (10 ng) or phosphate buffered solution (PBS) in 10-day interval, or were left untouched. Ten days after the second injection, the guinea pigs were sacrificed, the enucleated eyes underwent histological and immune-histological examinations. RESULTS: The rabbit eyes with EGF injections versus the contralateral untouched eyes did not show significant differences in intraocular pressure (7.5 ± 2.4 mmHg vs. 6.8 ± 2.2 mmHg; P = 0.66), retinal thickness (158 ± 5 µm vs. 158 ± 3 µm; P = 1.0), cell counts in the retinal ganglion cell layer (3.3 ± 1.7 cells/150 µm vs. 3.0 ± 1.4 cells/150 µm; P = 0.83), inner nuclear layer (46.4 ± 23.2 cells/150 µm vs. 39.6 ± 6.4 cells/150 µm; P = 0.61), and outer nuclear layer (215 ± 108 cells/150 µm vs. 202 ± 47 cells/150 µm; P = 0.83), or any apoptotic retinal cells. The guinea pig eyes injected with amphiregulin versus eyes with PBS injections did not differ (P = 0.72) in the degree of microglial activation, and both groups did not differ from untouched eyes in number of apoptotic retinal cells and retinal gliosis. CONCLUSIONS: Intravitreal applications of EGF (100 ng) in rabbits nor intravitreal applications of amphiregulin (10 ng) in guinea pigs led to intraocular specific inflammation or any observed intraocular destructive effect. The findings support the notion of a compatibility of intraocular applied EGF and amphiregulin. Springer Netherlands 2021-03-13 2021 /pmc/articles/PMC8172503/ /pubmed/33713254 http://dx.doi.org/10.1007/s10792-021-01761-w Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Paper Bikbov, Mukharram M. Khalimov, Timur A. Cerrada-Gimenez, Marc Ragauskas, Symantas Kalesnykas, Giedrius Jonas, Jost B. Compatibility of intravitreally applied epidermal growth factor and amphiregulin |
title | Compatibility of intravitreally applied epidermal growth factor and amphiregulin |
title_full | Compatibility of intravitreally applied epidermal growth factor and amphiregulin |
title_fullStr | Compatibility of intravitreally applied epidermal growth factor and amphiregulin |
title_full_unstemmed | Compatibility of intravitreally applied epidermal growth factor and amphiregulin |
title_short | Compatibility of intravitreally applied epidermal growth factor and amphiregulin |
title_sort | compatibility of intravitreally applied epidermal growth factor and amphiregulin |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8172503/ https://www.ncbi.nlm.nih.gov/pubmed/33713254 http://dx.doi.org/10.1007/s10792-021-01761-w |
work_keys_str_mv | AT bikbovmukharramm compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin AT khalimovtimura compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin AT cerradagimenezmarc compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin AT ragauskassymantas compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin AT kalesnykasgiedrius compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin AT jonasjostb compatibilityofintravitreallyappliedepidermalgrowthfactorandamphiregulin |